Get the Stockscreener App
70.23
1.61%
-1.15
Corcept Therapeutics Inc stock is traded at $70.23, with a volume of 953.29K.
It is down -1.61% in the last 24 hours and down -3.75% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$71.38
Open:
$70.62
24h Volume:
953.29K
Relative Volume:
0.62
Market Cap:
$7.72B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
55.74
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-3.49%
1M Performance:
-3.75%
6M Performance:
+17.84%
1Y Performance:
+164.02%
1-Day Range:
$69.74
$71.27
1-Week Range:
$67.00
$75.41
52-Week Range:
$26.53
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
70.23 | 7.72B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Investor Network: Corcept Therapeutics Incorporated. to Host Earnings Call - ACCESS Newswire
Corcept Therapeutics chief development officer sells $524,652 in stock - Investing.com Australia
Insider Sell: William Guyer Sells Shares of Corcept Therapeutics Inc (CORT) - GuruFocus
High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2025 Earnings Call Transcript - Insider Monkey
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall - MSN
Corcept Therapeutics price target lowered to $135 from $150 at Truist - Yahoo Finance
Corcept Therapeutics (NasdaqCM:CORT) Reports US$21M Q1 Net Income Lowers EPS - Yahoo Finance
Corcept Therapeutics (CORT) Faces Price Target Cut Amid Revenue Concerns | CORT Stock News - GuruFocus
Assessing Corcept Therapeutics: Insights From 9 Financial Analysts - Benzinga
Truist Cuts Price Target on Corcept Therapeutics to $135 From $150, Keeps Buy Rating - marketscreener.com
H.C. Wainwright cuts Corcept Therapeutics target to $145 By Investing.com - Investing.com Nigeria
Corcept Therapeutics (CORT) Receives Revised Price Target from A - GuruFocus
Corcept Therapeutics (CORT) Maintains Buy Rating Amid Revised Price Target | CORT Stock News - GuruFocus
Corcept Therapeutics Inc Q1 2025 Earnings: EPS of $0.17 Beats Es - GuruFocus
Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Operational Challenges - GuruFocus
Decoding Corcept Therapeutics Inc (CORT): A Strategic SWOT Insig - GuruFocus
Corcept Therapeutics Reports Q1 2025 Financial Results - TipRanks
Corcept Therapeutics Stock Jumps On Record Prescription Volume: Retail Sentiment Soars - MSN
Corcept: Q1 Earnings Snapshot - MySA
Corcept Therapeutics (CORT) Anticipates Future Growth Amid Reven - GuruFocus
Corcept Therapeutics (CORT) Set to Announce Q1 Earnings - GuruFocus
Earnings call transcript: Corcept Therapeutics Q1 2025 earnings beat expectations By Investing.com - Investing.com UK
Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates - Yahoo Finance
Corcept (NASDAQ:CORT) Misses Q1 Sales Targets, Stock Drops - Yahoo
Corcept Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CORCEPT THERAPEUTICS Earnings Results: $CORT Reports Quarterly Earnings - Nasdaq
Corcept Therapeutics Q1 Earnings Decrease, Revenue Rises -- Shares Fall After Hours - marketscreener.com
Corcept Therapeutics (CORT) Reports Q1 Revenue Miss | CORT Stock News - GuruFocus
Corcept Therapeutics Inc Q1 2025 Earnings: EPS of $0.17 Beats Estimates, Revenue of $157.2M Misses Expectations - GuruFocus
Corcept Therapeutics misses revenue estimates, stock falls By Investing.com - Investing.com UK
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE | CORT Stock News - GuruFocus
Corcept Earnings: $157M Revenue and Breakthrough ALS Survival Data Spark Pipeline Momentum - Stock Titan
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Bluefield Daily Telegraph
Corcept Therapeutics (CORT) Pre-Earnings Options Activity Suggests Modest Movement | CORT Stock News - GuruFocus
Corcept Therapeutics (CORT): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years? - Insider Monkey
BlackRock, Inc. Reduces Stake in Corcept Therapeutics Inc - GuruFocus
Corcept Therapeutics to Report Q1 Earnings: What's in the Cards? - Nasdaq
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS - GuruFocus
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL | CORT Stock News - GuruFocus
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL - Business Wire
3 Healthcare Stocks That Concern Us - Yahoo Finance
Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today - Benzinga
March sees multiple phase III successes, boosting Corcept and Mineralys - BioWorld MedTech
Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - MSN
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSEL - GuruFocus
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 | CORT Stock News - GuruFocus
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 - Business Wire
Corcept: Maintaining Strong Buy Even After Q4 Revenue And Earnings Miss - Seeking Alpha
Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes | CORT Stock News - GuruFocus
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):